Background:

SB202190 (FHPI) is a potent p38 MAPK inhibitor that specifically inhibits p38α and p38β with IC50 values of 50 and 100 nM, respectively [1].

SB202190 has been reported to potently enhance the growth of leukemia cell lines THP-1 and MV4-11. SB202190 activates the phosphorylation ERK and C-Raf. Studies have shown that the ED50?values of U0126 and FPT inhibitor II were significantly decreased in the presence of SB202190 [2].

SB202190 triggers changes in cell cycle profiles both during HU treatment and caffeine-induced PCC?(premature chromosome condensation) in plants. Moreover, SB202190 and caffeine decrease independently HU-induced histone H4 Lys5 acetylation [3].

参考文献:
[1] Davies SP1,?Reddy H,?Caivano M,?Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J.?2000 Oct 1;351(Pt 1):95-105.
[2] Hirosawa M1,?Nakahara M,?Otosaka R,?Imoto A,?Okazaki T,?Takahashi S. The p38 pathway inhibitor?SB202190?activates MEK/MAPK to stimulate the growth of leukemia cells. Leuk Res.?2009 May;33(5):693-9.
[3] Winnicki K1,?Maszewski J. SB202190 affects cell response to hydroxyurea-induced genotoxic stress in root meristems of Vicia faba. Plant Physiol Biochem.?2012 Nov;60:129-36.